Director – Medical Communications & Congress Strategy
Syndax
Director – Medical Communications & Congress Strategy
Syndax
Biopharmaceutical company developing oncology therapies
Syndax Pharmaceuticals is looking for a Director, Medical Communications & Congress Strategy
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
The Role:
The Director, Medical Communications & Congress Strategy is responsible for leading the development and execution of integrated medical communications and scientific engagement strategies across marketed products and pipeline programs. This role drives multichannel healthcare professional engagement, oversees medical congress and sponsored education initiatives, and ensures the delivery of high-quality, compliant scientific content that supports Medical Affairs objectives. Working closely with cross-functional stakeholders including Medical Strategy, Publications, Medical Information, Field Medical, Regulatory, Legal, and Compliance, the Director establishes communication priorities, manages budgets and vendor partnerships, and leverages performance metrics to optimize scientific exchange, customer engagement, and overall medical impact.
Key Responsibilities:
Desired Experience/Education and Personal Attributes:
Location: Syndax’s corporate office is in New York, NY.
Syndax offers a total compensation and rewards package that is among the most competitive in the industry. Base pay is just one element of our package and is determined within a range based on several factors including market data, experience, qualifications, demonstrated skills, relevant education or training, travel requirements and internal equity. Our overall package also includes an equity offering, annual target bonuses, and an outstanding benefits program. The anticipated annualized salary range for this role is $220,000 - $245,000.
About Syndax:
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#LI-Remote
Syndax Pharmaceuticals focuses on developing therapies for cancer. Its work centers on researching, testing through clinical trials, and commercializing cancer drugs, with an emphasis on difficult-to-treat cancers such as HR+ HER2- breast cancer. The company’s lead asset is Entinostat, which is being studied in combination with Exemestane for HR+ HER2- breast cancer; results from these trials will influence its growth and market position. Syndax funds its R&D and operations through capital raises and potential licensing or partnerships, and generates revenue by selling approved medicines. Its goal is to bring new cancer treatments to patients who have limited options by advancing promising oncology therapies and securing successful regulatory approvals and partnerships to scale those therapies.
Explore more opportunities at Syndax